Know Labs, Inc. (NYSE:KNW, now OTC Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and diverse other fields of use through its newly initiated Know Labs Technology Licensing (KTL) initiative, today reported financial results for the first quarter of the fiscal year 2025. Financial Highlights: In Q1 FY 2025, Know Labs reported a net loss of $4.67 million dollars, compared to a net loss of $3.45 million dollars in Q1 FY 2024, an increase in net loss of 35.4%. This translates to earnings per share of a loss of $0.04, unchanged from the prior year earnings per share loss

Know Labs, Inc. (NYSE:KNW, now OTC Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and diverse other fields of use through its newly initiated Know Labs Technology Licensing (KTL) initiative, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2025 ended on December 31, 2024, on February 14, 2025, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at https://ir.knowlabs.co, beginning at 1:15 pm PT. The webcast will also be available for replay at the company's website. For m

Know Labs Continues Trading as "KNWN" on the OTC Market Know Labs, Inc. (NYSE:KNW, now OTC Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today it has filed an appeal of the NYSE American's commencement of proceedings to delist Know Labs from its exchange. The Company will continue working on certain curative actions to regain compliance to maintain its listing while it awaits its appeal to the Listings Qualifications Panel of the Exchange. The Company's stock will be suspended from trading on the NYSE American during this time. NYSE Regulation is commencing delisting proceedings in connection with its d

Know Labs Trading as "KNWN" on the OTC Market Know Labs, Inc. (NYSE:KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today it is working on certain curative actions to regain compliance to maintain its listing and appeal the NYSE's determination to delist its common stock to the Listings Qualifications Panel of the Exchange. The company's stock will be suspended from trading on the NYSE American during this time. NYSE Regulation is commencing delisting proceedings in connection with its determination, announced today, that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE Americ

Company to Drive Monetization of its Patented Platform Technology Across Diverse Industries Know Labs, Inc. (NYSE:KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), is proud to announce the formation of its new business unit, Know Labs Technology Licensing, (KTL). Modeled after the successful Qualcomm Technology Licensing (QTL) framework, KTL will be dedicated to licensing Know Labs' robust intellectual property (IP) portfolio to corporate partners, academic institutions and research organizations, fostering innovation and accelerating the adoption of RFDS platform technology across a broad range of industries and the academic a

Know Labs, Inc. (NYSE:KNW) (the "Company"), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a registered direct offering with gross proceeds to the company of  $300K before deducting placement agent fees and other estimated expenses payable by the Company. This was a unit offering comprised of one share of stock and one warrant. The purchase price of the unit was $0.24 a share and the warrant is exercisable at $0.24. The warrants will expire on the fifth anniversary of the warrant issuance. The warrants also have a cashless exercise option in certain circumstances. This was a registered direct offering priced at-the-market under NYSE Ameri

Know Labs, Inc. (NYSE:KNW), leading developer of non-invasive diagnostics technology, today announced that on December 10, 2024, it received notification (the "Acceptance Letter") from the NYSE American LLC (the "NYSE American") that the Company's previously-submitted plan to regain compliance with the NYSE American's listing standards (the "Plan") was accepted. In the Acceptance Letter, NYSE American granted the Company until March 27, 2026 (the "Plan Period"), to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Compan

The Company Responds to Shareholder Concerns and Reiterates Progress and Future Plans Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive diagnostics technology released this morning an overview of its Form 10-K annual report for its fiscal year ending September 30, 2024, and provided reassurance regarding its progress over the past year, its plans and the state of its financial stability in light of its auditor required going concern opinion. Know Labs (the "Company") issued a press release on November 15, 2024, regarding the receipt of an audit opinion with a going concern explanation from its independent registered public accounting firm. The filing of that press release

Know Labs, Inc. (NYSE:KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed on November 14, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in Note 2 to the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guid

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Financial Highlights: Know Labs reported a net loss of $16.58 million dollars in FY2024, compared to a net loss of $15.29 million dollars in FY2023, an increase in net loss of 8.4%. This translates to Earnings Per Share of a loss of $0.20, better than FY2023 Earnings Per Share Loss of $0.41, an improvement of 51%, before preferred stock dividends. In FY2024, recorded a non-cash charge to earnings of $4.93 million, compared to $4.77 million FY2023. The non-cash items include (i) depreciation

4/A - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the establishment of a Scientific Advisory Board (SAB) comprised of distinguished researchers, innovators and experts in medical technology and human health. SAB members will advise the company and its strategic partners on advancing the company's progress in algorithm refinement, device development, clinical trial design and research publication strategy. SAB members will be working alongside Know Labs' current Medical and Regulatory Advisory Board members who have been supporting the team since 2020 and will be pivotal in helping Know Labs accelerate the development and deliver